Compare Moderna, Inc. (MRNA) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Under Armour Inc Class A — how do they compare? Moderna, Inc. trades at $63.81 (market cap $24.18B), while Under Armour Inc Class A trades at $5.28 (market cap $2.26B). The key difference: Moderna, Inc. is far larger — about 10.7× Under Armour Inc Class A's market cap, and Moderna, Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| MRNA | UAA | |
|---|---|---|
Market Cap | $24.18B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $8.14 |
52-Week Low | $22.36 | $4.17 |
Enterprise Value | $20.33B | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Under Armour (UAA) is trading at $5.265, down 10.15% with bearish technical signals despite recent earnings beats. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.7B in 2024 to $5.2B in 2025. Recent Q1 2027 earnings showed a profit beat but weaker revenue and cautious guidance, reflecting ongoing struggles in North American and Asia-Pacific markets. Cash flow remains negative at -$362M for 2025, though valuation ratios like P/S of 0.46 appear attractive relative to peers.
The outlook remains challenging with persistent revenue declines and profitability issues offset by potential value opportunities. Key risks include weak consumer spending, inventory management challenges, and competitive pressures. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels, though institutional sentiment appears cautious given the technical bearish signals and fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
